PRPH My guess is because the analyst lowered his price target from $25 to $9 about a year ago is what caused the beef. Yesterday, Karkus said he hasn't talked to the guy in about a year. The guy paints a dark picture that the company is worried that Covid testing is ending and thus the company is in a mad scramble to figure out some new business and is grasping at straws with genomics testing and getting in to biotech without understanding of the process.
In the call yesterday, Karkus thinks these are perhaps the best two deals of his career.
So I'd say the two guys are somewhat at odds lol.
Karkus has also been pretty insistent that the covid testing is not only not ending, but they've also expanded their lab into all other types of testing. The analyst seems to be more focused on the idea that this was supposed to be a covid-only company and they shouldn't be changing into something else. But of course that isn't even the history of the company. Karkus is more of a "let's get into any business that makes money" kind of guy.
News 
Market Data 
Discover 
AI
